Dear Editor in Chief,

The paper titled “Efficacy, safety, and impact of fluorescein in frameless stereotactic needle biopsies – a case series” provides the usefulness and safety of fluorescein in frameless stereotactic needle biopsies for intracranial lesion diagnosis are covered in this research [1]. In this study, patients who had fluorescein biopsies and those who did not were compared. The findings showed that the diagnostic success rate for the fluorescein group was much greater (93%) than for the non-fluorescein group (70%). This shows that fluorescein improves biopsies’ accuracy, perhaps by enabling real-time tumor tissue viewing, which lessens the need for multiple tissue samples and lowers the possibility of problems. The results of the study are especially noteworthy in light of the difficulties in performing stereotactic needle biopsies, including the possibility of sample mistakes and the requirement for several tissue samples in order to obtain a precise diagnosis. By increasing the visibility of tumor tissue, fluorescein looks to alleviate these problems. This could result in a higher rate of definitive diagnosis, shorter surgical times, and less related hazards. The addition of fluorescein does not raise the risk of unfavorable events, since the fluorescein group’s complication rates were comparable to those of the non-fluorescein group. The single-center design and the retroactive nature of the non-fluorescein group are two of the study’s flaws though. These elements might restrict how broadly the results can be applied. Furthermore, although the study emphasizes the advantages of fluorescein in lesions that enhance contrast, its efficacy in lesions that do not enhance contrast is yet unknown [2]. To validate these results and investigate the wider utility of fluorescein in neurosurgical oncology, more investigation is needed. This could include multicenter trials and studies contrasting fluorescein with other fluorescent drugs, such as 5-ALA.